Xeloda - xeloda.com : Metastatic Breast Cancer, Metastatic Colorectal Cancer, and Adjuvant Colon Cancer Treatment

3.18 Rating by ClearWebStats

xeloda.com is 2 decades 7 years 6 months old. This website has a #1,820,275 rank in global traffic. It has a .com as an domain extension. This website has a Google PageRank of 5 out of 10. This domain is estimated value of $ 480.00 and has a daily earning of $ 2.00. It is also listed in Dmoz. While no active threats were reported recently by users, xeloda.com is SAFE to browse.

Updated 1 decade 11 months ago

Get Custom Widget

Traffic Report of Xeloda

Daily Unique Visitors:	264
Daily Pageviews:	528

Estimated Valuation

Income Per Day:	$ 2.00
Estimated Worth:	$ 480.00

Search Engine Indexes

Google Indexed Pages:	211
Yahoo Indexed Pages:	Not Applicable
Bing Indexed Pages:	6,980

Search Engine Backlinks

Google Backlinks:	18
Bing Backlinks:	Not Applicable
Alexa BackLinks:	99

Safety Information

Google Safe Browsing:	No Risk Issues
Siteadvisor Rating:	No Risk Issues
WOT Trustworthiness:	Good
WOT Privacy:	Good
WOT Child Safety:	Good

Website Ranks & Scores

Google Pagerank:
Alexa Rank:	1,820,275
Domain Authority:	41 ON 100

Google Pagerank

PR 5 out of 10

PageSpeed Score

Siteadvisor Rating

No Risk Issues

Where is xeloda.com server located?

Hosted IP Address:

72.34.128.211

Hosted Country:

Location Latitude:

37.6524

Location Longitude:

-122.43

Social Engagement

Facebook Shares:	20
Facebook Likes:	47
Facebook Comments:	21
Twitter Count (Tweets):	Not Applicable
Linkedin Shares:	Not Applicable
Delicious Shares:	5

Page Resources Breakdown

Homepage Links Analysis

Page Title of Xeloda

Metastatic Breast Cancer, Metastatic Colorectal Cancer, and Adjuvant Colon Cancer Treatment | XELODA® (capecitabine)

Meta Description of Xeloda

Official Site for XELODA(R) (capecitabine) tablets for the treatment of metastatic colorectal and breast cancer as well as adjuvant colon cancer treatment. Learn more about XELODA (capecitabine)(R) oral chemotherapy medicine. XELODA is indicated as a single agent for adjuvant treatment in patients with Dukes' C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. XELODA was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Physicians should consider results of combination chemotherapy trials, which have shown improvement in DFS and OS, when prescribing single-agent XELODA in the adjuvant treatment of Dukes' C colon cancer. XELODA is indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with XELODA monotherapy. Use of XELODA instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage. XELODA monotherapy is indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated, eg, patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents. Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen. XELODA in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. Boxed WARNING and Contraindications Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulants such as warfarin and phenprocoumon should have their anticoagulant response (INR or prothrombin time) monitored frequently in order to adjust the anticoagulant dose accordingly. Altered coagulation parameters and/or bleeding, including death, have been reported during concomitant use. XELODA is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency, severe renal impairment, or known hypersensitivity to capecitabine or to any of its components or to 5-fluorouracil. Additional Serious Adverse Reactions Additional serious adverse reactions include diarrhea, cardiotoxicity, hand-and-foot syndrome, and hyperbilirubinemia. XELODA can cause fetal harm. Advise women of the potential risk to the fetus. Do not treat patients with neutrophil counts

Meta Tags of Xeloda

xeloda, capecitabine, capecitabine chemotherapy, oral chemotherapy tablets, oral chemotherapy, oral chemotherapy for breast cancer, 5 fu chemotherapy, metastatic colorectal cancer treatment, adjuvant chemotherapy colon cancer, metastaticbreast cancer treatment

Website Inpage Analysis

H1 Headings:	Not Applicable	H2 Headings:	1
H3 Headings:	12	H4 Headings:	2
H5 Headings:	Not Applicable	H6 Headings:	Not Applicable
Total IFRAMEs:	1	Total Images:	14
Google Adsense:	Not Applicable	Google Analytics:	UA-37696723-1

HTTP Header Analysis

Http-Version: 1.1
Status-Code: 200
Status: 200 OK
Date: Sun, 26 May 2013 13:01:37 GMT
X-Powered-By: Servlet 2.4; JBoss-4.3.0.GA_CP06 (build: SVNTag=JBPAPP_4_3_0_GA_CP06 date=200907141446)/JBossWeb-2.0
Content-Language: en-US, en
Connection: close
Content-Type: text/html;charset=ISO-8859-1

Domain Information for xeloda.com

Domain Registrar:	ENOM, INC.
Registration Date:	1996-10-23 2 decades 7 years 6 months ago
Last Modified:	2012-09-23 1 decade 1 year 7 months ago
Expiration Date:	2013-10-22 1 decade 6 months 1 week ago
Owner's E-Mail:	[email protected]

Domain Nameserver Information

Host		IP Address	Country
hlrns1.roche.com		198.21.25.33	United States
ns1.roche.com		196.3.50.135	Switzerland

DNS Record Analysis

Host	Type	TTL	Extra
xeloda.com	A	3599	IP:72.34.128.211
xeloda.com	NS	3600	Target:hlrns1.roche.com
xeloda.com	NS	3600	Target:ns1.roche.com
xeloda.com	SOA	3600	MNAME:ns1.roche.com RNAME:global.hostmaster.roche.com Serial:2012121150 Refresh:10800 Retry:3600 Expire:604800
xeloda.com	TXT	3600	TXT:v=spf1 ip4:196.3.51.163 ~all